Results 41 to 50 of about 29,485 (291)

Bp-Bs, a Novel T-cell Engaging Bispecific Antibody with Biparatopic Her2 Binding, Has Potent Anti-tumor Activities

Molecular Therapy: Oncolytics, 2019
Patients with Human epidermal growth factor receptor type 2 (Her2) overexpression are associated with aggressive tumor growth and poor clinical outcomes.
Jiayu Liu, Xiaoqiong Wu, Limin Lin, Haitao Pan, Yanlan Wang, Yumei Li, Yining Zhao, Zhong Wang   +7 more
doaj   +1 more source

Bispecific antibodies in cancer immunotherapy [PDF]

Current Opinion in Biotechnology, 2020
Among antibody-based cancer therapies, bispecific antibodies (biAbs) have gained momentum in preclinical and clinical investigations following the regulatory approvals of the trailblazing T-cell engaging biAb (T-biAb) blinatumomab. Discussed herein are recent strategies that aim at boosting the potency and mitigating the toxicity of T-biAbs, broadening
openaire   +2 more sources

Effective cancer immunotherapy combining mRNA-encoded bispecific antibodies that induce polyclonal T cell engagement and PD-L1-dependent 4-1BB costimulation

Frontiers in Immunology
BackgroundImmune checkpoint inhibitors have revolutionized cancer therapy, but many patients fail to respond or develop resistance, often due to reduced T cell activity.
Oana Hangiu, Oana Hangiu, Oana Hangiu, Rocío Navarro, Susana Frago, Laura Rubio-Pérez, Laura Rubio-Pérez, Laura Rubio-Pérez, Antonio Tapia-Galisteo, Antonio Tapia-Galisteo, Antonio Tapia-Galisteo, Laura Díez-Alonso, Laura Díez-Alonso, Laura Díez-Alonso, Marina Gómez-Rosel, Marina Gómez-Rosel, Marina Gómez-Rosel, Noelia Silva-Pilipich, Noelia Silva-Pilipich, Lucía Vanrell, Cristian Smerdou, Cristian Smerdou, Kenneth A. Howard, Laura Sanz, Luis Álvarez-Vallina, Luis Álvarez-Vallina, Luis Álvarez-Vallina, Marta Compte   +27 more
doaj   +1 more source

Bispecific antibodies in cancer immunotherapy [PDF]

Human Vaccines & Immunotherapeutics, 2016
Cancer immunotherapy has recently generated much excitement after the continuing success of the immunomodulating anti-CTLA-4 and anti-PD-1 antibodies against various types of cancers. Aside from these immunomodulating antibodies, bispecific antibodies, chimeric antigen receptor T cells, and other technologies are being actively studied.
Siqi, Chen, Jing, Li, Qing, Li, Zhong, Wang   +3 more
openaire   +2 more sources

Format chain exchange (FORCE) for high-throughput generation of bispecific antibodies in combinatorial binder-format matrices

Nature Communications, 2020
Bispecific antibodies have been generated in many different formats and it is becoming clear that rational design alone cannot create optimal functionalities.
Stefan Dengl, Klaus Mayer, Felix Bormann, Harald Duerr, Eike Hoffmann, Bianca Nussbaum, Michael Tischler, Martina Wagner, Andreas Kuglstatter, Lea Leibrock, Can Buldun, Guy Georges, Ulrich Brinkmann   +12 more
doaj   +1 more source

CAR T‐Cell Therapy in Neurology: A Scoping Review of Neuro‐Oncology, Autoimmune Diseases & Neurotoxicity

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Chimeric antigen receptor (CAR) T‐cell therapy has been investigated in neurological diseases, encompassing both central nervous system malignancies and autoimmune disorders, thereby extending its application beyond hematological cancers.
Omar Alqaisi, Mohammed Dibas, Patricia Tai, Ala Dibas, Osama Souied, Suhair Al‐Ghabeesh   +5 more
wiley   +1 more source

Affinity‐Tuned Albumin Hitchhiking Extends the Bioorthogonal Capture Window in Pretargeting Radiotheranostics

Advanced Healthcare Materials, EarlyView.
Pharmacokinetic engineering of clickable radioligands was achieved via albumin hitchhiking approach within a pretargeted radiotheranostics delivery platform. This approach reduced rapid renal elimination, expanded bioorthogonal capture window, boosted tumor uptake by ∼3.5‐fold, and improved the tumor‐to‐liver ratio by ∼6‐fold.
Xie He, Nicholas L. Fletcher, Gayathri R. Ediriweera, Yifei Zhu, James Humphries, Christopher B. Howard, Jiazheng Wang, Craig A. Bell, Kristian Kempe, Kristofer J. Thurecht   +9 more
wiley   +1 more source

Decoding the Mechanism of Action of a Parasite TGFβ Antagonist Inspires the Creation of Cell‐Type‐Specific TGFβ Modulators

Advanced Science, EarlyView.
The mammalian TGFβ interacts with ubiquitously expressed TGFBR1 and TGFBR2, and current TGFβ‐targeting agents are non‐cell‐selective. The cooperative interaction of the modular parasite TGFβ antagonist with multiple host (co‐)receptors empowers the design of TGM chimeras and bispecific antibodies that activate or inhibit TGFβ signaling in a cell ...
Maarten van Dinther, Tristin Schwartze, Jiying Zhang, Kun Fan, Gerard van der Zon, Luke Power, Cynthia S. Hinck, Claire Ciancia, Ananya Mukundan, Roman Gonzalez‐Prieto, Peter van Veelen, Rick M. Maizels, Andrew P. Hinck, Peter ten Dijke   +13 more
wiley   +1 more source

Protocol for high-throughput cloning, expression, purification, and evaluation of bispecific antibodies

STAR Protocols, 2022
Summary: Bispecific antibodies are a powerful new class of therapeutics, but their development often requires enormous amounts of time and resources.
Danqing Li, Alexander C. Partin, Liangjun Zhao, Irwin Chen, Mark L. Michaels, Zhulun Wang, Fernando Garces, Danyang Gong, Timothy P. Riley   +8 more
doaj   +1 more source

The use of non-radioactive iodine as a label in immunoassays [PDF]

, 1995
The research described in this thesis has centered on the development of a nonradioactive iodine label for use in immunoassays. A protein can be iodinated with nonradioactive iodine, used in an immunoassay, and the iodine label detected by a chemical ...
Butler, Mary
core